Nucleic acid therapeutics are entering a new phase. Oligonucleotides, long associated with rare disease, are now advancing into large, chronic indications across cardiovascular, metabolic, and liver disease, while conjugate-based delivery is beginning to extend their reach to muscle, the central nervous system, and other tissues beyond the liver. This expansion raises new scientific and commercial questions: how antisense and siRNA approaches compare, how biomarker effects translate into clinical outcomes, how conjugates and other extrahepatic delivery strategies can be optimized, and how manufacturing can scale to meet the volume and cost demands of large patient populations. Alongside oligonucleotides, mRNA, DNA, and newer modalities continue to broaden the field's therapeutic, prophylactic, and research applications.
Nucleic Acid Insights is a peer-reviewed, open-access journal providing the technical depth and strategic perspective required to navigate this rapidly evolving field. It serves all stakeholders active in or entering the space, including developers, manufacturers, tool and service providers, investors, and regulators.
Coverage is organized around five channels:
Nucleic Acid Insights covers all the major nucleic acid modalities, including but not limited to:
It also covers plasmid and synthetic DNA, guide RNA (gRNA) and gene editing, microRNA (miRNA) and other non-coding RNAs, and emerging formats such as circular and self-amplifying RNA.
Nucleic Acid Insights - your one-stop-shop for comprehensive coverage of process and analytical development, supply chain, preclinical and clinical R&D, regulation, business/finance, and commercial/market access.